Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: Three-year results of the RAVEL trial

Jean Fajadet, Marie Claude Morice, Christoph Bode, Paul Barragan, Patrick W. Serruys, William Wijns, Constantino R. Constantini, Jean Léon Guermonprez, Hélène Eltchaninoff, Didier Blanchard, Antonio Bartorelli, Gert Jan Laarman, MarcoAntonio Perin, J. Eduardo Sousa, Gerhard Schuler, Ferenc Molnar, Giulio Guagliumi, Antonio Colombo, Ernesto Ban Hayashi, Egon Wülfert

Research output: Contribution to journalArticlepeer-review


Background - The use of sirolimus-eluting coronary stents has been associated with a nearly complete elimination of restenosis at 6 months and with a very low 1-year incidence of major adverse cardiac events (MACE). This analysis examined whether these beneficial effects persist over the longer term. Methods and Results - This multicenter trial randomly assigned 238 patients to revascularization of single, de novo, native coronary artery lesions with sirolimus-eluting versus conventional bare-metal stents. Survival free from target lesion revascularization (TLR), target vessel failure (TVF), and MACE up to 3 years of follow-up was compared between the 2 treatment groups. Complete data sets were available in 94.2% of patients treated with sirolimus-eluting stents and in 94.1% of patients randomized to the control group. The cumulative 1-, 2-, and 3-year event-free survival rates were 99.2%, 96.5%, and 93.7% for TLR and 95.8%, 92.3%, and 87.9% for TVF, respectively, in the sirolimus-eluting stent group, versus 75.9%, 75.9%, and 75.0% for TLR and 71.2%, 69.4%, and 67.3% for TVF in the control group (P

Original languageEnglish
Pages (from-to)1040-1044
Number of pages5
Issue number8
Publication statusPublished - Mar 1 2005


  • Coronary disease
  • Follow-up studies
  • Restenosis
  • Sirolimus
  • Stents

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: Three-year results of the RAVEL trial'. Together they form a unique fingerprint.

Cite this